SG11201805913QA - New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents

New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them

Info

Publication number
SG11201805913QA
SG11201805913QA SG11201805913QA SG11201805913QA SG11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA
Authority
SG
Singapore
Prior art keywords
international
utca
berkshire
budapest
pct
Prior art date
Application number
SG11201805913QA
Other languages
English (en)
Inventor
Attila Paczal
Zoltán Szlávik
András Kotschy
Maïa Chanrion
Ana Leticia Maragno
Olivier Geneste
Didier Demarles
Balázs Bálint
Szabolcs Sipos
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of SG11201805913QA publication Critical patent/SG11201805913QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201805913QA 2016-01-19 2016-12-19 New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them SG11201805913QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1650411A FR3046792B1 (fr) 2016-01-19 2016-01-19 Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2016/081688 WO2017125224A1 (en) 2016-01-19 2016-12-19 New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
SG11201805913QA true SG11201805913QA (en) 2018-08-30

Family

ID=55752504

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805913QA SG11201805913QA (en) 2016-01-19 2016-12-19 New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them

Country Status (43)

Country Link
US (1) US10457689B2 (ru)
EP (1) EP3405471B1 (ru)
JP (1) JP6871275B2 (ru)
KR (1) KR20180098677A (ru)
CN (1) CN108602841B (ru)
AU (1) AU2016387870B2 (ru)
BR (1) BR112018014536B1 (ru)
CA (1) CA3011761C (ru)
CL (1) CL2018001908A1 (ru)
CO (1) CO2018007443A2 (ru)
CR (1) CR20180363A (ru)
CU (1) CU20180073A7 (ru)
CY (1) CY1122560T1 (ru)
DK (1) DK3405471T3 (ru)
EA (1) EA036932B1 (ru)
EC (1) ECSP18053634A (ru)
ES (1) ES2760545T3 (ru)
FR (1) FR3046792B1 (ru)
GE (1) GEP20207126B (ru)
HR (1) HRP20192073T1 (ru)
HU (1) HUE048449T2 (ru)
IL (1) IL260550B (ru)
LT (1) LT3405471T (ru)
MA (1) MA43639B1 (ru)
MD (1) MD3405471T2 (ru)
ME (1) ME03555B (ru)
MX (1) MX2018008808A (ru)
MY (1) MY196352A (ru)
NI (1) NI201800076A (ru)
PE (1) PE20190336A1 (ru)
PH (1) PH12018501506A1 (ru)
PL (1) PL3405471T3 (ru)
PT (1) PT3405471T (ru)
RS (1) RS59622B1 (ru)
RU (1) RU2743098C2 (ru)
SA (1) SA518392049B1 (ru)
SG (1) SG11201805913QA (ru)
SI (1) SI3405471T1 (ru)
SV (1) SV2018005722A (ru)
TN (1) TN2018000239A1 (ru)
UA (1) UA123508C2 (ru)
WO (1) WO2017125224A1 (ru)
ZA (1) ZA201804770B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3565547B1 (en) * 2017-01-06 2024-03-13 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
UA126920C2 (uk) 2017-06-22 2023-02-22 Ле Лаборатуар Сервьє Комбінація інгібітору mcl-1 і стандартного лікарського препарату для лікування гематологічних злоякісних новоутворень, її застосування та фармацевтичні композиції, що її містять
CN111818917A (zh) 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
US20200255451A1 (en) * 2017-08-15 2020-08-13 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
TW201920193A (zh) * 2017-08-15 2019-06-01 美商艾伯維有限公司 大環mel-1抑制劑以及使用方法
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
EP3891156B1 (en) * 2018-12-06 2023-11-15 Les Laboratoires Servier New crystalline forms of a thienopyrimidine as mcl-1 inhibitor
KR20220017931A (ko) 2019-05-20 2022-02-14 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
EP4038072A4 (en) * 2019-10-03 2023-08-02 California Institute Of Technology MCL1 INHIBITORS AND USES THEREOF
WO2022115451A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
TW202315637A (zh) 2021-06-11 2023-04-16 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
TW202317200A (zh) 2021-06-11 2023-05-01 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
EP0981337A4 (en) * 1997-02-09 2003-03-12 Pharmos Corp IMPROVED ANTI-ANGIOGENIC ACTIVITY OF CONSTANTLY LOADED DERIVATIVES OF STEROID HORMONES
US7776867B2 (en) * 2004-06-29 2010-08-17 Amgen Inc. Furanopyrimidines
BRPI0817681A2 (pt) * 2007-10-16 2015-04-14 Wyeth Llc Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase
EP2276346B1 (en) * 2008-04-30 2016-11-23 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
WO2010054285A2 (en) * 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
RU2015118985A (ru) * 2012-11-14 2017-01-10 Ф. Хоффманн-Ля Рош Аг Производные имидазопиридина
ES2680935T3 (es) * 2013-05-02 2018-09-11 F. Hoffmann-La Roche Ag Derivados de purina como agonistas del receptor CB2
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EP3405471A1 (en) 2018-11-28
PL3405471T3 (pl) 2020-04-30
ES2760545T3 (es) 2020-05-14
PT3405471T (pt) 2019-12-05
JP2019511559A (ja) 2019-04-25
ZA201804770B (en) 2021-08-25
SA518392049B1 (ar) 2022-08-04
PE20190336A1 (es) 2019-03-07
US10457689B2 (en) 2019-10-29
MY196352A (en) 2023-03-24
SV2018005722A (es) 2018-10-10
HRP20192073T1 (hr) 2020-02-21
AU2016387870B2 (en) 2021-04-01
BR112018014536A2 (pt) 2018-12-11
GEP20207126B (en) 2020-06-25
MD3405471T2 (ro) 2020-02-29
CN108602841B (zh) 2021-03-23
CY1122560T1 (el) 2021-01-27
CN108602841A (zh) 2018-09-28
CL2018001908A1 (es) 2019-01-04
RU2018129308A3 (ru) 2020-02-20
RU2018129308A (ru) 2020-02-20
IL260550B (en) 2021-06-30
EP3405471B1 (en) 2019-10-30
UA123508C2 (uk) 2021-04-14
RU2743098C2 (ru) 2021-02-15
CA3011761C (en) 2020-10-27
NI201800076A (es) 2018-09-20
KR20180098677A (ko) 2018-09-04
SI3405471T1 (sl) 2020-02-28
EA201891622A1 (ru) 2019-01-31
EA036932B1 (ru) 2021-01-18
LT3405471T (lt) 2019-12-10
ECSP18053634A (es) 2018-07-31
CR20180363A (es) 2018-08-22
MA43639B1 (fr) 2020-02-28
MX2018008808A (es) 2018-09-21
WO2017125224A1 (en) 2017-07-27
DK3405471T3 (da) 2020-01-27
TN2018000239A1 (en) 2020-01-16
US20190031677A1 (en) 2019-01-31
CU20180073A7 (es) 2018-11-06
HUE048449T2 (hu) 2020-07-28
BR112018014536B1 (pt) 2022-10-11
RS59622B1 (sr) 2020-01-31
CA3011761A1 (en) 2017-07-27
CO2018007443A2 (es) 2018-07-19
FR3046792A1 (ru) 2017-07-21
PH12018501506A1 (en) 2019-04-08
FR3046792B1 (fr) 2018-02-02
ME03555B (me) 2020-07-20
JP6871275B2 (ja) 2021-05-12
AU2016387870A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
SG11201805913QA (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
SG11201810576QA (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201900077QA (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201809299QA (en) Formulations of an lsd1 inhibitor
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201407533SA (en) Antiviral compounds
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SG11201811416VA (en) Crystalline solid forms of a bet inhibitor
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201908660RA (en) N-substituted indole derivatives
SG11201900689RA (en) Compounds and compositions and uses thereof
SG11201808686VA (en) Synthesis of indazoles
SG11202000494UA (en) Drug delivery composition
SG11201903326RA (en) Liposomal formulation for use in the treatment of cancer